Tillotts Pharma AG announces launch of Asacol 800 mg tablets in the People’s Republic of China


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴
Tillotts Pharma enters China

Tillotts Pharma AG, part of the Japanese Zeria Group, is pleased to announce the recent launch of Asacol® 800 mg tablets (mesalazine) as first-line treatment for mild to moderate ulcerative colitis (UC) in the People’s Republic of China (“China”).

After announcing the successful partnership of Tillotts and Menarini in October 2019, and regulatory approval of Asacol® 800 mg in April 2020, the launch of the tablets represents a major milestone for both companies. Bringing Asacol® to the market began several years ago with the conduct of two Phase III studies in the local population. The introduction of this high strength mesalazine tablet formulation to the Chinese market is expected to optimise the therapeutic options of patients living with UC in China.

Mattias Norrman, Chief Operations Officer at Tillotts, said, “We are very excited that we have now launched Asacol in China and made it available to Chinese patients. This has been achieved through the close partnership between Tillotts and Menarini and the efforts and continued dedication of the teams involved. Providing the highest strength mesalazine tablet in the Chinese market may help improve patient adherence to chronic ulcerative colitis treatment. It is always a great satisfaction to ensure that UC patients around the world receive new first-line treatment opportunities.”

Mattias Norrman added, “The commercial launch of Asacol® tablets will bring new treatment options in tablet formulation to clinicians. There is a substantial need for new treatment options in UC. According to statistics from the Chinese Center for Disease Control and Prevention, it is estimated that by 2025, the number of patients in China with IBD; a type of chronic non-specific intestinal inflammation, including ulcerative colitis and Crohn’s disease, will reach 1.5 million[1].”

Tags : #TillotaPharma #China #Asacol #AsacolLaunchedChina #Menarini #smitakumar #medicircle

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026